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Abstract Extent of resection of glioblastoma (GBM)
correlates with overall survival. Fluorescence-guided
resection (FGR) using 5-aminolevulinic acid (5-ALA) can
improve the extent of resection. Unfortunately not all
patients given 5-ALA accumulate sufficient quantities of
protoporphyrin IX (PpIX) for successful FGR. In this study,
we investigated the effects of dexamethasone, desipramine,
phenytoin, valproic acid, and levetiracetam on the produc-
tion and accumulation of PpIX in U87MG cells. All of these
drugs, except levetiracetam, reduce the total amount of PpIX
produced byGBM cells (p\ 0.05).When dexamethasone is
mixed with another drug (desipramine, phenytoin, valproic
acid or levetiracetam) the amount of PpIX produced is
further decreased (p\ 0.01). However, when cells are
analyzed for PpIX cellular retention, dexamethasone accu-
mulated significantly more PpIX than the vehicle control
(p\ 0.05). Cellular retention of PpIX was not different
from controls in cells treated with dexamethasone plus
desipramine, valproic acid or levetiracetam, but was sig-
nificantly less for dexamethasone plus phenytoin
(p\ 0.01). These data suggest that medications given
before and during surgery may interfere with PpIX accu-
mulation in malignant cells. At this time, levetiracetam
appears to be the best medication in its class (anticonvul-
sants) for patients undergoing 5-ALA-mediated FGR.
Keywords Glioma  5-Aminolevulinic acid 
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Introduction
Patients with glioblastoma multiforme (GBM) have a less
than 5 % 5-year survival rate [1]. The extent of resection is
the most important treatment-related variable for improv-
ing prognosis [2]. Extent of resection can be limited by the
difficulty of discriminating between tumor and adjacent
white matter. An emerging tool to achieve maximal safe
resection and thereby increase overall survival is the use of
5-aminolevulinic acid (5-ALA) for fluorescence-guided
resection (FGR). 5-ALA is selectively taken up by neo-
plastic cells and metabolized to protoporphyrin IX (PpIX).
PpIX fluorescence under light of 400-410 nm allows neu-
rosurgeons to distinguish neoplastic from non-neoplastic
tissue. Unfortunately, not all patients given 5-ALA before
surgery accumulate sufficient PpIX in their malignant cells
to make the use of FGR. This may in part be due to
medications administered in the perioperative period.
5-ALA is a precursor compound for porphyrin produc-
tion in the heme biosynthesis pathway [3]. Stummer and
colleagues showed that rat C6 glioma cells metabolize
5-ALA and accumulate excess PpIX in vitro and in vivo
permitting fluorescent detection [4]. Subsequent clinical
trials confirmed the effectiveness of 5-ALA for FGR with
better resection rates and improved overall survival [5–8].
Volumetric analysis showed that PpIX fluorescence
extends beyond the enhancing tumor margin on MRI [9].
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5-ALA administration may not only assist in resection, it
may also be used as a diagnostic tool. In one study, 100 %
of fluorescent positive biopsies were later confirmed by
tissue staining as malignant or high-grade brain neoplasms
[10]. Further, urine analysis of PpIX in GBM patients may
provide a non-invasive diagnostic tool for the disease.
Utsuki et al. analyzed urine as a predictive model for
intraoperative fluorescence and found that 100 % of
glioblastoma, 50 % of benign astrocytoma and 50 % of
metastatic brain tumor patients exhibited PpIX fluorescent
urine 2 h after 5-ALA administration [11].
Prescreening for PpIX accumulation in the urine may
help determine which patients will respond to 5-ALA
during surgery [11], but it does not explain why some
patients do not accumulate adequate PpIX for detection
during surgery. Removal of the 5-ALA/PpIX compounds
from the cell and/or ferrochelatase activity may result in
poor PpIX accumulation. The ATP-binding cassette trans-
porter ABCG2 shuttles porphyrins out of cells, and
blocking ABCG2 function results in porphyrin accumula-
tion [12]. ABGC2 transporters are also known to transport
anticancer drugs out of malignant cells and are overex-
pressed and correlated with tumor grade in glioma [13]. In
addition, the silencing of ferrochelatase production in
glioma cells lines using siRNA augments PpIX accumu-
lation and fluorescence [14]. It has also been hypothesized
that medications may interfere with the cells ability to
metabolize 5-ALA and/or accumulate PpIX [15].
Anticonvulsants are commonly used in the management
of seizures in brain tumor patients. In 2012, Hefti and
coworkers, reported that phenytoin, but not levetiracetam,
interferes with metabolism of 5-ALA and the production of
PpIX in glioma cells [15]. Additionally, there are other
classes of drugs used prior and during surgery that may
interfere with 5-ALA metabolism and/or PpIX accumula-
tion. Here we expand on the previous work with phenytoin
and levetiracetam to investigate the effects of dexametha-
sone (corticosteroid), desipramine (antidepressant), and
valproic acid (anticonvulsant) on the production and
accumulation of PpIX in GBM cells using an in vitro
model system to measure relative PpIX fluorescence [16].
Methods
Cell lines
U-87 MG cells (ATCC, Manassas, VA, USA) were pre-
viously stably transfected with the yellow fluorescent
protein (YFP) expression vector pEYFP-C1 (YFP-U87)
[16]. YFP-U87 Cells were cultured in standard conditions
with Eagle’s Minimum Essential Medium (EMEM)
(Lonza, Portsmouth, NH, USA), 10 % fetal bovine serum
(Atlanta Biologicals, Norcross, GA, USA), 0.2 mg/mL
G418 (Gold Biotechnology, St. Louis, MO, USA) and 1 %
penicillin/streptomycin/amphotericin B (PSA) (Lonza,
Portsmouth, NH, USA).
Cell number to YFP fluorescence correlation
YFP-U87s were re-suspended in phenol red-free Dul-
becco’s Modified Eagle Medium supplemented with L-
glutamine (Lonza, Portsmouth, NH, USA) and 10 % FBS.
Cells were serially diluted and plated in black-bottom
microtiter plates (Greiner Bio-One, Monroe, NC, USA).
Four replications per plate were used for each of four
separate assays. The cells were allowed to adhere to the
plates for 4 h. A Modulus Microplate Reader (Promega
BioSystems, Sunnyvale, CA, USA) measured YFP fluo-
rescence due to its constitutive production within the YFP-
U87 cells, using a standard 525 nm excitation/580–640 nm
emission filter. Relative light units (RLU) from these YFP
fluorescence recordings were plotted against cell number to
determine the correlation between YFP production and cell
number.
Treatments
Dexamethasone, desipramine hydrochloride, 5,5-diphenyl-
hydantoin (phenytoin), valproic acid sodium salt, and
levetiracetam (Sigma, St Louis, MO, USA) were dissolved
in dimethyl sulfoxide (DMSO) (Amresco, Solon, OH,
USA) before diluting in phenol red-containing EMEM
supplemented with 10 % FBS and 1 % penicillin/strepto-
mycin/amphotericin B. Two sets of treatment media were
created: one with a single treatment, and another with the
single treatment plus the addition of a therapeutic con-
centration of dexamethasone. All drugs for administration
in cell culture were within therapeutic plasma concentra-
tions as referenced on the brand drug product sheets or
cited in the literature when not reported on the product
sheet: *25–160 ng/mL dexamethasone in first 6 h after
dosing [17], 50–300 ng/mL desipramine (Norpramin pro-
duct sheet), 10–20 lg/mL phenytoin (Dilatin product
sheet), 50–125 lg/mL valproic acid (Stavzor product
sheet), and the effective levetiracetam dose of 11 lg/mL
[18]. The final concentrations used were 100 ng/mL dex-
amethasone, 300 ng/mL Desipramine, 20 lg/mL pheny-
toin, 50 lg/uL valproic acid, 11 lg/mL levetiracetam
(Table 1). Control media was also prepared with either
0.1 % DMSO, for comparison to single treatment groups,
or 0.2 % DMSO, for comparison with single treatment with
the addition of a therapeutic concentration of dexametha-
sone in order to control for treatment vehicle effects.
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Treatment of YFP-U87s
Each treatment group was represented with at least six
replicates per assay and completed in triplicate. YFP-U87s
were plated at a density of 15,000 cells per well in black-
bottom, 96-well microplates (Greiner Bio-One, Monroe,
NC, USA). Cells were allowed to adhere to the plate
overnight, then fresh media containing the treatments or
DMSO vehicle was added to the respective treatment
groups to create therapeutic concentrations of each medi-
cation within the wells. Treatment groups (Table 1) were
dexamethasone, desipramine, phenytoin, valproic acid,
levetiracetam, 0.1 % DMSO (positive control), 2X dex-
amethasone, desipramine ? dexamethasone, pheny-
toin ? dexamethasone, valproic acid ? dexamethasone,
levetiracetam ? dexamethasone, 0.2 % DMSO (positive
control) and negative control (no treatment, no 5-ALA).
Positive controls without DMSO (5-ALA only) were also
tested. Treatment containing media was replaced with fresh
treatment media at 24 and 48 h consistent with previous
studies in the literature [15].
5-Aminolevulinic acid treatment
After 72 h of drug treatment, all treatment groups were
washed with EMEM without phenol red supplemented with
4 mM L-glutamine (Gibco, LifeTechnologies, Grand
Island, NY, USA) and 10 % FBS. After washing, 100 lL
of EMEM without phenol red containing 2 mM 5-ALA
(Acros Organics, Thermo Fisher Scientific, Pittsburg, PA,
USA), 4 mM L-glutamine, 10 % FBS, 30 lg/mL insulin
(Sigma-Aldrich, St. Louis, MO, USA), 0.1 % DMSO, and
2 % v/v of 0.1 mM EDTA (Thermo Fisher Scientific,
Pittsburg, PA, USA) was added to each well. All groups,
except the negative controls, then received 5-ALA treat-
ment media and incubated in standard cell culture condi-
tions for 4 h protected from light.
PpIX production and accumulation
PpIX and YFP fluorescence was measured using a Modulus
Microplate Reader with a 525 nm excitation/580-640 nm
emission filter to detect YFP fluorescence and a 405 nm
Table 1 Medication treatment groups and difference in PpIX production/retention relative to appropriate DMSO positive control
Treatments Drug class Drug concentration DMSO (%) 5-ALA Production (%) p value Retention (%) p value
Dexamethasone Corticosteroid 100 ng/mL 0.1 Yes -44 ± 4 \0.01 30 ± 12 \0.05
Desipramine Antidepressant 300 ng/mL 0.1 Yes -12 ± 6 \0.01 -11 ± 8 =0.055
Valproic Acid Anticonvulsant 50 lg/mL 0.1 Yes -25 ± 4 \0.01 -28 ± 5 \0.01
Phenytoin Anticonvulsant 20 lg/mL 0.1 Yes -31 ± 5 \0.01 -40 ± 10 \0.01
Levetiracetam Anticonvulsant 11 lg/mL 0.1 Yes 7 ± 7 [0.05 6 ± 10 [0.05
0.1 % (-) Control – – 0.1 No -86 ± 6 \0.01 -120 ± 8 \0.01
0.0 % (?) Control – – – Yes 23 ± 8 \0.01 4 ± 8 [0.05
0.1 % (?) Control – – 0.1 Yes – – – –
2X Dex Corticosteroid 200 ng/mL 0.2 Yes -46 ± 4 \0.01 26 ± 9 \0.05
Des ? Dex AD ? C 300 ? 100 ng/mL 0.2 Yes -36 ± 7 \0.01 14 ± 9 [0.05
Val ? Dex AC ? C 50 lg/mL ? 100 ng/mL 0.2 Yes -33 ± 3 \0.01 -9 ± 7 [0.05
Phe ? Dex AC ? C 20 lg/mL ? 100 ng/mL 0.2 Yes -55 ± 3 \0.01 -43 ± 8 \0.01
Lev ? Dex AC ? C 11 lg/mL ? 100 ng/mL 0.2 Yes -35 ± 4 \0.01 -3 ± 11 [0.05
0.2 % (-) Control – – 0.2 No -87 ± 6 \0.01 -124 ± 10 \0.01
0.0 % (?) Control – – – Yes 9 ± 7 [0.05 23 ± 10 \0.01
0.2 % (?) Control – – 0.2 Yes – – – –
Dex dexamethasone, Des desipramine, Val valproic acid, Lev levetiracetam, Phe phenytoin, AD antidepressant, AC anticonvulsant,
C corticosteroid
Production = % Increase (? Value) or Decrease (- Value) in Total PpIX in Cells ? Media Compared to Appropriate DMSO Control
Retention = % Increase (? Value) or Decrease (- Value) in PpIX Found Only Within Cells (Media Removed)
The negative controls include either 0.1 or 0.2 % DMSO without 5-ALA
The positive controls include either 0.1 or 0.2 % DMSO with 2 mM 5-ALA
All % changes are normalized to either 0.1 % DMSO controls for single drug treatments or 0.2 % DMSO controls for dual drug treatments
Values are mean ± standard error
J Neurooncol (2016) 127:15–21 17
123
excitation/580–640 nm emission filter (Promega Corpora-
tion, Madison, WI, USA) to detect PpIX fluorescence.
PpIX and YFP fluorescence was measured in the same
plate in sequential fashion in order to analyze the total
production of PpIX after 4 h. Briefly, after measuring total
fluorescence in the well, the media was aspirated from all
wells and fluorescence was again measured to determine
the amount of PpIX retained within the cells. Treatment
group data were normalized by subtracting the average
relative light unit (RLU) value of the non-5-ALA treated
wells from the 5-ALA treated wells. PpIX total production
per well (readings with media) and retention by cells
(readings after aspiration) were then calculated by deter-
mining a PpIX/YFP quotient (dividing PpIX RLU by YFP
RLU). The PpIX/YFP quotient provides a relative value for
the PpIX production per cell mass in the well. The treat-
ment PpIX/YFP quotients were compared to the 5-ALA
plus DMSO treated groups to detect statistical differences.
A Paired-Samples T test was performed to determine sig-
nificant differences between respective treatment groups
and the appropriate DMSO containing vehicle control.
Results
YFP-U87 standard curve
The YFP-U87 standard curve had a strong positive Pearson
correlation coefficient (r = 0.987) indicating a significant
linear relationship between YFP RLU and cell number
(Fig. 1).
Effects of medication treatment on the total
production of PpIX
PpIX production quotients for total fluorescence were
compared for each treatment combination. All treatments,
except levetiracetam, experienced a significant decrease
(p\ 0.05) in the total PpIX production quotient compared
to the 0.1 % DMSO control group, as shown in Fig. 2a.
The greatest reduction of PpIX produced was found in the
dexamethasone and phenytoin groups, with approximately
Fig. 1 Yellow fluorescent protein (YFP) light emission correlates
with cell number. Relative light units (RLU) were plotted against the
number of YFP-U87 cells 4 h following plating in a 96-well
microplate. Analysis was completed using raw data from nine
experiments. The Pearson correlation coefficient was 0.987
(r2 = 0.975) and confirms a strong, direct relationship between cells
plated and YFP fluorescence as shown previously [16]
(a)
(b)
Fig. 2 Single medication treatment of cells reduces PpIX production
or retention in cells. Relative PpIX fluorescence (PpIX fluorescence
per cell) is shown as a percent difference of relative light units
(DRLU) between treatment groups and the 0.1 % DMSO positive
control. Relative PpIX fluorescence was determine by calculating a
PpIX RLU/YFP RLU quotient. YFP-U87 cells were treated with a
single medication for 72 h before application of 2 mM 5-ALA and
plates were read 4 h later. a The relative total production of PpIX
(readings of cells ? media in wells) was significantly less in all
groups compared to the 0.1 % DMSO control, except levetiracetam.
b The relative retention of PpIX in cells was determined by removing
the media prior to measuring fluorescence. Values are presented as the
percent difference from the 0.1 % DMSO positive control. While
dexamethasone treated cells produced significantly less PpIX com-
pared to controls, the dexamethasone reduces the efflux of the PpIX
from the cells. Dex dexamethasone, Des desipramine, Phe phenytoin,
Val valproic acid, Lev levetiracetam, *p\ 0.05, p\ 0.01
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44 and 31 % reduction, respectively. Because brain tumor
patients are often given these drugs in combination with
dexamethasone, YFP-U87 cells were also treated with
dexamethasone plus one of the other medications. The
reduction of PpIX in response to these medication combi-
nations was additive. Desipramine, which resulted in 12 %
reduction of PpIX, further reduced PpIX production to
36 % in the presence of dexamethasone. Likewise,
phenytoin, which resulted in 31 % reduction in PpIX,
further reduced PpIX production to 55 % in the presence of
dexamethasone. While levetiracetam alone did not reduce
PpIX production, the addition of dexamethasone signifi-
cantly reduced PpIX production (Fig. 3a).
Effects of treatments on cellular retention of PpIX
PpIX retention quotients for intraellular fluorescence were
compared for each treatment combination. Dexamethasone
treated cells, which produced lower total levels of PpIX,
was the only treatment group that retained more PpIX
within the cells (p\ 0.05; Fig. 2b). Compared to controls,
the amount of intracellular PpIX after phenytoin and val-
proic acid treatment was significantly less (p\ 0.05) while
unchanged following desipramine and levetiracetam treat-
ments. In the presence of dexamethasone, PpIX retention
varied depending on the treatment combination (Fig. 3b).
The addition of dexamethosone to desipramine, valproic
acid and levetiracetam treatments had no effect on intra-
cellular PpIX compared to controls. However, when added
to phenytoin, dexamethasone intracellular PpIX remained
significantly lower compared to controls (p\ 0.05).
Discussion
Fluorescence guided resection of brain tumors is an
important addition to the surgical management of brain
tumors. Yet, not all tumors display adequate PpIX fluo-
rescence after 5-ALA administration. We tested several
medications commonly prescribed to brain tumor patients,
alone or in combination, to determine if they might alter
metabolism of 5-ALA and/or retention of PpIX in GBM
cells. The novel findings of our study include: (1) dexam-
ethasone, desipramine, and valproic acid appear to inhibit
production of PpIX, (2) the addition of dexamethasone to
the other drugs tested further reduced PpIX production, and
(3) although dexamethasone reduced the amount of PpIX
produced more than any other drug tested, it promotes the
retention of PpIX within cells.
These findings were derived using the YFP/PpIX fluo-
rescence quotient model [16]. It is important to note that
these data were collected using the cell line, YFP-U87
cells. As demonstrated previously by Hefti et al. [15], the
responses of U-87MG cell line to levetiracetam or pheny-
toin were indistinguishable from the responses seen in
another GBM cell line (U373 MG) or primary GBM cul-
tures in both cell growth and PpIX production [15]. While
the conclusions obtained in the present study are consistent
with the Hefti et al. study, it will be important to follow up
this study with additional cell lines and primary cultures, as
the cellular heterogeneity within glioma tumors may result
in different responses to drug treatment.
Because of glioma’s infiltrative properties, tumor mar-
gins are not clearly defined and make gross total resection
(a)
(b)
Fig. 3 Dual medication treatment of cells further reduces PpIX
production or retention in cells. Relative PpIX fluorescence (PpIX
fluorescence per cell) is plotted as the percent difference of relative
light units (DRLU) between treatment groups and the 0.2 % DMSO
positive control. YFP-U87 cells were treated with both medications
for 72 h before application of 2 mM 5-ALA and plates were read 4 h
later. a After 4 h, the total relative production of PpIX was
determined by taking readings with cells and media in the wells.
There was a reduction in the production quotients (PpIX RLU/YFP
RLU) for all dual drug treatments, with several combinations
(Des ? Dex; Phe ? Dex; Lev ? Dex) appearing to have a strong
synergistic PpIX reduction. b The relative retention of PpIX was
unchanged in cells treated with two drugs (drug ? Dex) versus single
drug treatments. Dex = Dexamethasone, Des = Desipramine,
Phe = Phenytoin, Val = Valproic Acid, Lev = Levetiracetam,
*p\ 0.05, p\ 0.01
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difficult. The advantage of good intraoperative imaging
and/or visualization of the tumor is evident. Research and
case studies continue to report that 5-ALA improves total
resection rates and consequently progression free survival
[19, 20]. However, the difficulty of getting FDA approval
in the United States has generated interest in alternatives to
5-ALA FGR like intraoperative MRI [21], conjugated
chlorotoxin FGR [22] and fluorescein sodium FGR [23].
While these other resection modalities may improve total
resection over white light, it is yet to be determined if these
modalities are better at achieving gross total resection than
5-ALA [24, 25]. Interestingly, these alternative resection
aids may improve resection in an additive manner when
used in combination with 5-ALA as seen with intraopera-
tive MRI ? 5-ALA [19, 26].
The use of 5-ALA FGR can improve resection of glioma
and ultimately progression-free survival, but its use may
also be expanded to destroy residual tumor cells after
resection or to treat inoperable lesions using intraoperative
or stereotactic photodynamic therapy [27]. Photodynamic
therapy with 5-ALA is based upon the toxicity of PpIX
when excited by red light (630–635 nm) in combination
with oxygen [28]. This 5-ALA photodynamic therapy
releases singlet oxygen and causes apoptosis and necrosis
[28]. Although photodynamic therapy is not well estab-
lished for treatment of brain tumors, 5-ALA’s potential use
in this manner is intriguing. Stummer et al. (2008) reported
a long-term response in a ‘‘non-resectable, distant recur-
rence of glioblastoma multiforme’’ using 5-ALA photo-
dynamic therapy [27].
Unfortunately, not all tumors treated with 5-ALA gen-
erate adequate PpIX needed for FGR and photodynamic
therapy. Here we show that the medications used to man-
age brain tumor patients may interfere with the cell’s
ability to metabolize 5-ALA and accumulate intracellular
PpIX. Malignant glioblastoma cells (YFP-U87s) readily
convert 5-ALA to PpIX when they are not treated with
medication. All medications except levetiracetam lowered
total PpIX production. A noteworthy observation with the
dexamethasone treatment was that it acted as a strong
inhibitor of PpIX production, while promoting retention of
the PpIX within the cells. We also confirmed the previous
report that phenytoin, but not levetiracetam, interferes with
metabolism of 5-ALA and the production of PpIX in
glioma cells [15].
These data suggest that levetiracetam may be a better
choice for 5-ALA FGR when a preoperative anticonvulsant
is needed as it does not appear to decrease the production
and intracellular retention of PpIX as do phenytoin and
valproic acid. The antidepressant desipramine does not
have a significant affect upon PpIX accumulation in cells
even though it does reduce total PpIX production similarly
to the drugs dexamethasone, phenytoin and valproic acid.
Further studies on additional antidepressants are warranted
to determine what drugs may offer the best outcome for
5-ALA FGR. Lastly, dexamethasone, a common corticos-
teroid given to brain tumor patients to manage intracranial
pressure and vasogenic edema, may significantly reduce
the total amount of 5-ALA that is converted to PpIX.
Dexamethasone’s use in patients undergoing 5-ALA FGR
should be studied clinically to determine if it is truly dis-
rupting the tumor from fluorescing adequately for FGR.
The observation that cells treated with dexamethasone
were able to retain PpIX better than others will be followed
up in future work to determine the mechanism behind the
increase in retention. The authors acknowledge that drug
interactions alone may not be the primary reason behind a
lack of fluorescence in patients undergoing 5-ALA FGR.
Intrinsic cell pathways and the molecular events within
different cells may also alter PpIX production and retention
as shown in a recent study indicated where the mutation
status of IDH1 alone could significantly alter 5-ALA
mediated fluorescence [29].
In summary, we report that dexamethasone, desipra-
mine, phenytoin and valproic acid, but not levetiracetam
reduce PpIX production in GBM cells. We confirmed that
levetiracetam may possibly be a better choice for seizure
management in patients undergoing 5-ALA FGR. How-
ever, if the patient is also on dexamethasone, the benefits of
using levetiracetam may be offset. It seems evident that
medications are having an effect on PpIX production and
retention. Future work is warranted to determine the best
medications and combination of these drugs to achieve the
desired management of the patient’s symptoms, but also to
achieve the highest amount of tumor fluorescence. Opti-
mizing 5-ALA FGR may translate into 5-ALA photody-
namic therapy that effectively kills residual tumor cells
after surgery or to photokill inoperable tumors via stereo-
tactic photodynamic therapy.
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